Clinical epidemiology and research on HIV infection in Switzerland: The Swiss HIV cohort study 1988-2000

Schweizerische Medizinische Wochenschrift

Volumn 130, Issue 41, 2000, Pages 1493-1500

  Sudre, P ^a   Rickenbach, M ^a   Taffe, P ^a   Janin, P ^a   Volkart, A C ^a   Francioli, P ^a   Amiet, R ^a   Battegay, M ^a   Bernasconi, E ^a   Bucher, H ^a   Burgisser, Ph ^a   Egger, M ^a   Erb, P ^a   Fierz, W ^a   Flepp, M ^a   Furrer, H J ^a   Gorgievski, M ^a   Gunthard, H ^a   Grob, P ^a   Hirschel, B ^a   Kind, C ^a   Klimkait, Th ^a   Ledergerber, B ^a   Lauper, U ^a   Opravil, M ^a   Paccaud, F ^a   Pantaleo, G ^a   Perrin, L ^a   Pichler, W ^a   Piffaretti, J C ^a   Rudin, C ^a   Schiffer, V ^a   Schupbach, J ^a   Telenti, A ^a   Vernazza, P ^a   Weber, R ^a   more..

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

AIDS; Clinical; Cohort study; Epidemiology; HIV; Review

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COHORT ANALYSIS; HIGH RISK POPULATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; MORTALITY; OPPORTUNISTIC INFECTION; PRIMARY MEDICAL CARE; PROPHYLAXIS; QUALITY OF LIFE; RISK FACTOR; SEXUAL BEHAVIOR; SWITZERLAND;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; COHORT STUDIES; FEMALE; GEOGRAPHY; HIV INFECTIONS; HOSPITALS, UNIVERSITY; HUMAN; INCIDENCE; MALE; REGISTRIES; SUPPORT, NON-U.S. GOV'T; SWITZERLAND;

EID: 0034649112     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Impact of new antiretroviral combination therapies in HIV-infected patients in Switzerland: Prospective multicentre study
2. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
3. Poverty and prognosis of HIV infection in Switzerland
4. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland
5. + cell counts in HIV-infected patients
6. Early participation in a HIV cohort study slows disease progression and improves survival
7. Transforming laboratory test results to improve clinical outcome predictions in HIV patients
8. Predicting AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy
9. Cost-effectiveness of highly active antiretroviral therapy in HIV-infected patients
10. Risk of HIV-related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: Prospective cohort study
11. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 infection: A prospective cohort study
12. AIDS opportunistic illnesses occurring after initiation of highly active antiretroviral therapy
13. Low-risk of Pneumocystis carinii pneumonia and toxoplasmic encephalitis after stopping primary prophylaxis in HIV-1-infected adults treated with antiretroviral combination therapy
14. Why is highly active antiretroviral therapy not prescribed or why is it discontinued?
15. Severity and prognosis of acute human immunodeficiency virus type 1 illness: A dose-response relationship
16. + T cell decrease and the year of human immunodeficiency virus (HIV) type 1 seroconversion among persons enrolled in the Swiss HIV Cohort Study
17. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
18. A randomized double-blind controlled study of 6 months oral nutritional supplementation with arginine and Ω-3 fatty acids in HIV-infected patients
19. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study
20. Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: A randomized trial of double versus triple therapy. Swiss HIV Cohort Study
21. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. Swiss HIV Cohort Study
22. Cytomegalovirus retinitis: Decreased risk of bilaterality with increased use of systemic treatment
23. Reasons for failure of prevention of toxoplasma encephalitis
24. Disseminated Mycobacterium avium complex disease in the Swiss HIV Cohort Study: Increasing incidence, unchanged prognosis
25. Does pregnancy influence the natural course of HIV infection? Evidence from two large Swiss Cohort Studies
26. Antiretroviral therapies in pregnancy: Maternal, fetal and neonatal effects
27. Prevention of vertical HIV transmission: Additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group
28. Changes in renal function associated with indinavir
29. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
30. Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV-1 infection. Swiss HIV Cohort Study
31. Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study
32. Molecular epidemiology of HIV-1 in Switzerland: Evidence for a silent mutation in the C2V3 region distinguishing intravenous drug users from homosexual men. Swiss HIV Cohort Study
33. Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study
34. Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5/Δccr5) genotype is neither essential nor sufficient for protection against disease progression
35. CCR2 polymorphism and HIV disease
36. Is CD95 or CD26 expression on T-cells a marker for HIV non- or slow-progressor status?
37. Downregulation of Bcl-2, but not of Bax or Bcl-x, is associated with T lymphocyte apoptosis in HIV infection and restored by antiretroviral therapy or by interleukin-2
38. + lymphocytes in HIV-infection correlates with markers of disease severity and changes towards normalization under treatment
39. Enteric infections and diarrhea in human immunodeficiency virus-infected persons: Prospective community-based cohort study. Swiss HIV Cohort Study
40. Quality of life in asympromatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study
41. Time of initiation of antiretroviral therapy: Impact on HIV viraemia